| Identification | Back Directory | [Name]
2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid | [CAS]
223488-57-1 | [Synonyms]
CS-2325
CP-533536
Evatanepag
CP-533536 free acid
Evatanepag (CP-533536)
CP-533536;CP 533536;CP533536
EVATANEPAG;CP-533536;CP 533536
(3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid
2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid
2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]aceticaci
Acetic acid, 2-[3-[[[[4-(1,1-dimethylethyl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]-
2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid ISO 9001：2015 REACH | [Molecular Formula]
C25H28N2O5S | [MDL Number]
MFCD09833940 | [MOL File]
223488-57-1.mol | [Molecular Weight]
468.57 |
| Chemical Properties | Back Directory | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO:32.0(Max Conc. mg/mL);68.29(Max Conc. mM) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Evatanepag is an EP2 receptor selective prostaglandin E2 agonist that helps induce bone growth. | [Definition]
ChEBI: Evatanepag is a monocarboxylic acid. | [in vivo]
Evatanepag (0.3-3.0 mg/kg, directly injected into the marrow cavity of the tibia) promotes bone formation in rats[1].
Evatanepag (0.3, 3.0 mg/kg, intranasal administration, from day1 to day4) reduces HDM aeroallergen-induced increased RL response to methacholine in mice[2].
Evatanepag (1 mg/kg, intravenous injection) demonstrates high i.v. clearance (Cl: 56 mL/min/kg) and a short half-life (t1/2: 0.33 h)[1].
| Animal Model: | Rats[1] | | Dosage: | 0.3, 1.0, 3.0 mg/kg | | Administration: | Directly injected into the marrow cavity of the tibia
| | Result: | Dose-dependently increased in bone area, bone mineral content, bone mineral density. |
| Animal Model: | HDM (house dust mite)-sensitized BALB/c mice[2] | | Dosage: | 0.3 mg/kg, 3 mg/kg | | Administration: | Intranasal administration, from day1 to day4
| | Result: | Prevented aeroallergen-driven increased RL (lung resistance) at 0.3 mg/kg.
Prevented the enhanced MC activity by approximately 48% at 3 mg/kg.
|
| [IC 50]
EP2 |
|
|